Drug Delivery Company – Two Robust Platform Technologies Rich Product Pipeline – Active Partnering Strategy

Investor Presentation Spring 2011

www.accesspharma.com

This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio and pipeline and clinical programs of the combined company, the market opportunities for MuGard™, the sales of, market opportunities for and planned studies of ProLindac™, the market opportunities for Thiarabine and the Cobalamin programs, and the combined company’s goals and objectives. These statements are subject to numerous risks and uncertainties, including but not limited to the risks detailed in Access's Annual Report on Form 10-KSB for the year ended December 31, 2009, and other reports filed by the companies with the Securities and Exchange Commission.

These materials are not an offer to sell securities and are not soliciting an offer to buy securities.

For Additional Access Pharmaceuticals Information, Go to the Following Publicly Available Resources:

www.AccessPharma.com www.MuGard.com

at AccessPharma

at Access Pharmaceuticals

2

Safe Harbor Statement

  CobOral and CobaCyte Drug Delivery Platforms – Proprietary drug delivery platforms creates multiple product opportunities; mitigates single product/technology exposure.

  Late Stage Product Pipeline – Access has received FDA marketing clearance for oral mucositis product MuGard; ProLindac and Thiarabine have completed Phase 2 trials.

  Partnering Strategy – Access has completed eight partnerships or collaborations in the past 24 months: upfront payments, royalties, research costs, clinical costs.

  Experienced Team – Experienced chemists, pre-clinical and manufacturing experts, clinical development personnel, and business development and finance personnel.

  Focus on Shareholder Value – Management and board members are significant shareholders, focused on increasing shareholder value.

3

Corporate Overview & Highlights

Access Pharmaceuticals, Inc. (ACCP.OB) – a drug delivery company with late-stage products for cancer, diabetes and hormone replacement. Several products are based on Access’ proprietary drug delivery platform technologies.

4

Multiple Platforms Drives Opportunity

Oncology Pre-

clinical IND Phase 1 Phase 2 Phase 3 Product Potential

MuGard ™ Commercially Launched >$1B

ProLindac™ ~ $3 B

Thiarabine™ >$600 M

CobOral / CobaCyte – Drug Delivery Cobalamin Oral Insulin Moving toward Proof of Concept in Man Study >$1B

Human Growth Hormone >$1B

GLP-1; Other Injectables >$1B

Two proprietary, drug-delivery platform technologies enable product development across multiple biotechnology sub-sectors: Cancer, Diabetes, Hormone, Fertility, etc..

5

MuGard – Commercially launched in late 2010

6

MuGard™ - Treating A Significant Health Issue

Significant Medical Issue – Often Unrecognized, Undiagnosed and Undertreated

Well being Pain Problems with eating, drinking, speaking and swallowing Weight loss Impairment of quality of life e.g. mood

Infection Reduces infection barrier

Compromised treatment

Reduced dosage Breaks or delays in therapy affecting treatment outcomes

Economic impact

Prolonged hospital stays Increased use of resources e.g. feeding tube placement

  >$1 Billion Addressable Market: Target all cancer patients;

1.5 million US cancer patients annually (incidence). Roughly

90% of patients on radiation (43% severe); and 40% of

patients receiving chemotherapy.

  MuGard Stands Alone: Only oral mucositis product that

instructs pre-treatment; Safe to swallow on label.

  US Commercial Launch: US manufacturing completed –

launch activities underway.

  Multiple Marketing Partners: Partners signed for EU,

Switzerland, Norway, Iceland, China, Korea.

  Royalties: 20%, scaling to 25%

7

MuGard™ - Oral Mucositis (OM)

Large Unmet Medical Need – Commercially Launching in US, Europe and Far East

8

Indications: dryness or dry mouth associated with various conditions

Directions for use: Swish and spit out.

Indications: indicated for the management of pain and relief of pain…

Directions for use: Gargle and spit out.

Indications: “Magic mouthwash" prepared by pharmacists and used to treat mouth sores (oral mucositis)

Directions for use: Gargle and spit out

Indications: MuGard is indicated for the management of oral mucositis/ stomatitis

Directions for use: … rinse may be expelled or swallowed … safe to swallow …

…recommended that patients purchase MuGard™ prior to the commencement of cancer therapy ..

MuGard is recommended for preventative use MuGard can be swallowed to coat lesions in throat

MuGard’s Industry Leading Label

 Oncology Network Sampling Program   MuGard Centers-of Excellence   Broad-scale sampling program to top oncology networks to educate and

promote the benefit MuGard provides patients

 BioScrip (Nasdaq: BIOS) Specialty Distribution Partner   Nationwide distribution platform with extensive physician network   Live “stand-alone” retail pharmacies in over 30 top metro areas   75,000 square-foot mail distribution facility in Columbus, Ohio   Various order and delivery options for patient   Judicator of claims – handles insurance claims process

  iMedicor and Direct Medical Solutions   Non-personal online marketing capability   Direct Medical Solutions - direct sales reps   Supports other distribution channels

9

MuGard: US Distribution Strategy

  Achieved scale-up manufacturing of MuGard (Accupac) – product

manufactured and shipped to specialty distributor

  Key opinion leader collaboration (Dr. Stephen Sonis) – Oral Mucositis expert

  Launch sampling program – targeting large oncology networks to build

awareness and clinical experience with MuGard   Work with reimbursement consultants – filed reimbursement coding

application and discussions are ongoing with major third-party payers

  Additional MuGard clinical data, ongoing and at MASCC   Secure Additional Distribution Channels – Ongoing   Long-term Stability for full commercial availability   Additional MuGard partnerships

10

ACCP Remains On-track for Full-Scale North American MuGard Launch

MuGard: US Commercial Launch Activities

11

Cobalamin – oral drug delivery platform to enhance absorption of large molecules

12

CobOral / CobaCyte Drug Delivery Platforms

1 2

3

4

The nanoparticle coated with Cobalamin (red) binds to intrinsic factor (1), which in turn binds to its cell surface receptor (2).

The nanoparticle is transported across the cell (3), crosses the gut wall and enters the bloodstream (4).

Using The Body’s Own Vitamin B-12 Absorption System To Enable and Enhance Delivery of Drugs

The “Trojan Horse” Delivery Vehicle

Nanopolymer “payload” can be Insulin, growth hormone, EPO, etc.

13

  CobOral technology makes “active drug” look like Vitamin B-12; achieved significant levels of oral bioavailability with insulin and HGH

  Studies conducted on numerous products including Insulin, LHRH, EPO, Interferon, G-CSF

  Seeking co-development partner in diabetes field

  Potential for use in wide variety of disease states where vitamin intake is up regulated, including cancer, rheumatoid arthritis, Crohn’s, autoimmune disorders

CobOral Oral Insulin Program

Cobalamin Enhanced Nanopolymers – Enabling Oral Insulin Multiple CobOral Formulation Agreements In Place

Clinically Relevant Glucose Lowering Effect in Diabetic Rat Model

  CobOral Oral Insulin – Access has achieved unprecedented levels of oral bioavailability of insulin in two animal models ( >80% of that achieved by injection).

  Multiple Ongoing Collaborations – Oral insulin provided to collaborators that have confirmed high levels of oral bioavailability; new collaborations ongoing

  CobOral Human Growth Hormone – Demonstrated high oral bioavailability and a 25% improvement in weight gain in standard animal model

  Multiple Applications – Ongoing discussions with multiple potential partners looking at exploiting CobOral/CobaCyte oral drug delivery for insulin, HGH, fertility drugs, proteins, etc.

  Patent Life-cycle Management Tool –protect patent (IP) position through cobalamin formulation of existing drugs, resulting in new IP

  sRNAi – Adaptation of Cobalamin system to provide delivery vector for sRNAi therapeutics being evaluated; partnering and collaboration discussions ongoing

14

Significant Oral Bioavailability

Multiple Collaborations Driving Enhanced Data Set; Planning Initiation of Phase 1 Human Trial in Cobalamin Oral Insulin

15

ProLindac – Phase II cancer drug for solid tumors

  ProLindacTM – Access designed a second generation DACH platinum using our proprietary nano-polymer expertise.

  Eloxatin® •  FDA approved (2001) for front-line

metastatic colorectal cancer •  2008 $2.5+ billion projected sales globally •  Significant neurotoxicity

  Partnering On-going – Partnered with Aosaikang Med Group (ASK) in China and JCOM in Korea. Partners paid upfront, committed to run 3 clinical trials that ACCP controls, and royalties.

16

ProLindac™

Positioning ProLindac™ as a Replacement for Sanofi-Aventis’ Eloxatin Represents a $3+ Billion Market Opportunity

DACH Platinum (same active in Eloxatin) is inactive while attached to polymer background

Chelator releases platinum compound in low pH environment; e.g. tumor

  Monotherapy in relapsed, platinum-sensitive patients •  36 patients enrolled in six centers in France; final follow-up ongoing •  Heavily treated patients (at least 3, up to 7, previous regimens) •  Exploring two dosing schedules (once/two weeks and once/three weeks)

  Safety – ProLindac Exhibited Very Benign Safety Profile •  Patients tolerating drug well through multiple cycles (up to 10 or more) •  No Eloxatin-like neurotox; no nephrotox; no hematotoxicity; no worse emesis

  Efficacy and Activity – ProLindac “Outperforms” Current Best Care •  At highest doses, 66.7% ProLindac patients responded; Activity levels superior to oxali

or carbo in monotherapy in similar but healthier patient populations (approx 20%)

  Next Steps •  First combination trial launched: ProLindac plus taxol in recurrent ovarian; partners

planning additional combination trials (ProLindac plus Lilly’s Gemzar in liver and pancreatic cancer)

•  Partnering discussions ongoing

17

ProLindac™ Phase II Trial – Relapsed Ovarian

Final Study Results – Safe and Active DACH Platinum Drug

18

Thiarabine – Phase II cancer drug for Leukemias and Lymphomas

  New Nucleoside Analogue – Same class as other clinically successful FDA approved nucleoside analogues such as fludarabine and cladrabine; Clofarabine was approved after a single 44 patient study.

  Significant Data/Information Known – Drug was well tolerated and active in two previously conducted Phase II clinical trials in advanced solid tumors. Significant clinical pharmacology and dose scheduling information known.

  MD Anderson Cancer Center – Principal investigator is Hagop Kantarjian, M.D., Head of Leukemia Dept. at MD Anderson (same team of experts that have successfully led to approved nucleoside analogues in leukemias and lymphomas).

  Clinical Plan – Pre-clinical and clinical studies indicate strong potential in leukaemia or lymphoma. Based upon clinical data, ACCP is finalizing trial designs and protocols in AML, ALL, and B-cell lymphomas.

19

Thiarabine – A Novel Nucleoside Analogue

Significant Clinical Data Available – Initiated Phase I/II study at MD Anderson Cancer Center

  SpePharm, B.V. – MuGard marketing partner in European Union; rolling launch of MuGard ongoing in UK, Germany, Italy, Nordic countries, Greece; anticipated launches in France, Benelux, Spain and throughout EU continues.

  Aosaikang Medicinal Group (ASK) – Rights to ProLindac in greater China; provides second source manufacturing; obligated to pay for two controlled combination studies

  JCOM Ltd – Rights to ProLindac in Korea; obligated to pay for one pivotal controlled combination study.

  JCOM Ltd – Rights to MuGard in Korea; secured MuGard marketing approval and preparing commercial launch in 2010

  RHEI Pharma: – Rights to MuGard in greater China; securing regulatory approval, and seeking source of supply; preparing for commercial launch

  US Large Pharma – Multiple sponsored formulation agreements evaluating cobalamin oral drug delivery platform (various large molecules, insulin, GLP, HGH)

  US and European Biotechnology Company – Material transfer agreement and collaboration agreement

20

Active Partnering Strategy For Drug Programs

Active Business Development Effort; Securing Partnerships and Collaborations to Enhance Value and Share Costs

  Jeffrey B. Davis, Chief Executive Officer President, SCO Financial Group LLC; Senior Vice President and Chief Financial Officer of a healthcare technology company; Vice President, Corporate Finance, at Deutsche Morgan Grenfell; Senior marketing and product management positions at AT&T Bell Laboratories; Marketing and Product Manager at Philips Medical Systems North America. MBA, The Wharton School, University of Pennsylvania; BS Biomedical Engineering, Boston University.

  Esteban Cvitkovic, M.D., Vice Chairman, Senior Director, Clinical Oncology R&D Dr. Cvitkovic is a board-certified oncologist with more than 30 years experience in oncology therapeutics, including clinical research, clinical pharmacology, design of single-agent and combination regimens, and optimization of clinical efficacy. Dr. Cvitkovic played a fundamental role in the registration strategy and post-registration development of cisplatin and oxaliplatin. Dr. Cvitkovic has held staff and academic appointments at Memorial Sloan Kettering Cancer Center (NY), Columbia Presbyterian (NY), Hospital St. Louis (Paris), Instituto Mario Negri (Milan) and Institut Gustave Roussy (Villejuif).

  Frank Jacobucci, Vice President Sales & Marketing Mr. Jacobucci has over 20 years experience in sales management, including senior sales executive positions at oncology focused companies including MGI Pharma, Genetics Institute, Wyeth Oncology, Aventis, Precision Therapeutics and CRC Oncology Services.

  David P. Nowotnik, Ph.D., Senior Vice President Research and Development Senior Director, Product Development, Guilford Pharmaceuticals, Inc.; Group Leader, Bristol-Myers Squibb. Section Leader, Amersham International. Research Chemist, Tate and Lyle and Aspro-Nicholas. PhD, Organic Chemistry, University of London.

  Stephen B. Thompson, Vice President and CFO Controller and Administration Manager, API; Controller, Robert E. Woolley, Inc., a hotel real estate company; Controller, OKC Limited Partnership, an oil and gas company. Accounting and finance, Santa Fe International Corporation.

  Phillip Wise, Vice President Business Development and Strategy VP, Commercial and Business Development and Chief Financial Officer, Enhance Pharmaceuticals; VP, Commercial and Business Development, Ardent Pharmaceuticals; Director of Managed Care Marketing & Director of New Product Planning, Glaxo Wellcome; MBA, University of Virginia; BS, Industrial and Systems Engineering, Georgia Institute of Technology.

21

Experienced Management Team

  Steven H. Rouhandeh, Chairman Steve Rouhandeh is a Chief Investment Officer of SCO Capital Partners, L.P., a New York based life sciences fund. Steve also is a founder of SCO Financial Group LLC, a highly successful value-oriented healthcare group with 11-year track record in sector (advisory, research, banking and investing). Steve possesses a diverse background in financial services that includes experience in asset management, corporate finance, investment banking and law.

  Esteban Cvitkovic, M.D., Vice Chairman – see Management

  Mark Ahn, Ph.D. Dr. Ahn is currently Professor and Chair of the Science & Technology Entrepreneurship Faculties of Commerce & Administration and Science at the Victoria University of Wellington, in Wellington, New Zealand. Previously, Dr. Ahn was President and CEO of Hana Biosciences, Inc., and earlier, Vice President Hematology at Genentech, Inc. where he was responsible for Rituxan. Prior to that, Dr. Ahn held senior positions at Bristol-Myers Squibb, Amgen and FMC Corporation.

  Mark Alvino Mark Alvino is a Managing Director at Griffin Securities, a leading provider of corporate finance advisory and brokerage services to the life sciences industry. Prior to that, Mark was a Managing Director for SCO Securities, and additionally held several senior management positions within the investment banking and investor relations industries

  Stephen B. Howell, M.D. Dr. Howell is Professor of Medicine, University of California at San Diego, and has extensive experience in platinum therapeutics. Dr. Howell is also a Director of Clinical Investigation and Development Therapeutics Program, UCSD Cancer Center, and has previously received the Milken Foundation prize for contributions to cancer chemotherapy.

  Jeffrey B. Davis, Chief Executive Officer – see Management

22

Board of Directors

Strong Board of Directors with Relevant Experience

  Ticker: ACCP (OTCBB)   Capital Structure

Common shares outstanding 19.2 million shares

Common under preferred shares 11.7 million shares Total common shares 30.9 million shares

  Debt: $5.5 million note due end 2011, convertible at $27.50 per share.   Cash Burn: Roughly $4 million annually. With current cash on balance sheet and expected

upfront and milestone payments, Access has sufficient cash into 2012.   High Quality Institutional Investors: Includes SCO Capital Partners, Oracle Partners, CSFB,

Schroeder’s Bank

23

Financial Overview

  Global roll-out of MuGard for oral mucositis

  Initiate dose-escalating trial for Thiarabine

  Initiate ProLindac combination Phase 2 trial

  Multiple CobaOral / CobaCyte formulation agreements

  Far East launches of MuGard   Additional MuGard co-promotion / partnerships

  CobOral / CobaCyte collaborations and data

  ProLindac and Thiarabine clinical data

  Seek global or regional partnerships for ProLindac, Thiarabine, and

Cobalamin programs

24

Milestones / News Flow – 2011 and forward

Significant News Flow Anticipated in 2011 and 2012

  CobaOral / CobaCyte Drug Delivery Platforms – multiple long term opportunities (oral insulin, oral HGH, fertility drugs,etc.); multiple collaborations ongoing; launch Phase I human trial in oral insulin

  Late Stage Oncology Pipeline: Proprietary technology has created portfolio of new products for large markets

•  One FDA-Approved product, MuGard – North American launch; intro in Europe underway; Asia next; >$1 billion opportunity

•  One Phase 2/3-ready cancer drug, ProLindac – New form of proven drug, takes direct aim at Sanofi’s $2.5 billion Eloxatin franchise

•  One Phase 2-ready cancer drug, Thiarabine – superior version of clinically and commercially successful nucleoside analogue

  Commercial Strategy: Multi-local development and marketing partners to shift risk and share costs, while retaining very attractive revenue/royalty rights.

  Value Visibility: Seek “re-listing” on national exchange; actively present company to the investment community.

25

Conclusions – Investment Highlights

ACCP – An Undervalued Investment Opportunity